BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05462873 (QEQ278 in Advanced Solid Tumors): BVCT ex-ante prediction vs. reported outcome

On 2 Jul 2024, BioinvestGPT's BVCT predicted technical partial success and commercial failure for this trial. The 13 Feb 2026 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT05462873
Drug Name
QEQ278
Drug MoA
NKG2DL activator
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
Advanced Solid Tumors
Human Patients
30
Sponsor
Novartis
Phase
Phase 1

Prediction of , index 1645

Prospective Prediction
Prediction Index
1645
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit in OS as monotherapy or part of combotherapies)
Technical Prediction
partial SUCCESS (statistically maybe significant yet moderate clinical benefit in ORR/PFS as monotherapy) partial FAILURE (statistically insignificant additive clinical benefit in ORR/PFS in combination with anti-PD(L)1 therapies)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
591 days in advance
Readout Data Interpretation
MGY825's further development has been discontinued probably due to insufficient clinical benefit
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase I/Ib, Open-label, Multi-center, Study of QEQ278 in Patients With Advanced Solid Tumors
Phase
Phase 1
Status
Terminated
Enrollment
30
Lead sponsor
Novartis Pharmaceuticals
Conditions
Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Squamous Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck
Interventions
BIOLOGICAL: QEQ278
Design
Non randomized · Single group · None
Primary purpose
Treatment
Start
2023-04-04
Primary completion
2026-01-26
Completion
2026-01-26
Primary outcomes
  • Incidence and nature of Dose Limiting Toxicities (DLTs) during the DLT evaluation period for single agent QEQ278 (28 days)
  • Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (Up to 31 months)
  • Frequency of dose interruptions, reductions (Up to 30 months)
  • Dose intensity (Up to 30 months)

NCT05462873 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials